Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis

In non-dialysis-dependent chronic kidney disease (NDD-CKD), erythropoiesis-stimulating agents (ESAs) and iron supplementation are essential for anemia management. Ferric carboxymaltose (FCM) is a relatively novel intravenous iron formulation used in different clinical settings, although scarce data...

Descripción completa

Detalles Bibliográficos
Autores principales: Cirillo, Luigi, Somma, Chiara, Allinovi, Marco, Bagalà, Alfredo, Ferro, Giuseppe, Di Marcantonio, Elio, Bellelli, Stefania, Dallari, Lorenzo Antonio, Ballo, Piercarlo, Dattolo, Pietro Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018957/
https://www.ncbi.nlm.nih.gov/pubmed/33811227
http://dx.doi.org/10.1038/s41598-021-86769-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018957/
https://www.ncbi.nlm.nih.gov/pubmed/33811227
http://dx.doi.org/10.1038/s41598-021-86769-z

Ejemplares similares